Biotricity Q3 FY26 revenue up 10% to $4M; net loss narrows 13% to $1.1M

BIOTRICITY INC.

2026-Q3 EPS reported -$0.10 revenue$11,747,607

Revenue $4M (+10.2% YoY); gross margin expanded to 81.5% from 76.4%.
Net loss $1.1M ($0.042 per share) vs $1.3M ($0.054 per share) prior year.
Third consecutive quarter of positive EBITDA and net operating income.
Recurring TaaS revenue $3.6M (91.2% of total); customer retention 90%+.
FDA clearance for AI clinical model expected in coming months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.